NPJ Breast Cancer最新文献_第6页

Sequencing PARP inhibitors in breast cancer: lessons learned and emerging insights. 乳腺癌中PARP抑制剂的测序：经验教训和新见解。

IF 8.4 2区医学

NPJ Breast Cancer Pub Date : 2026-05-15 DOI: 10.1038/s41523-026-00963-8

Kenan Aloss, Mallory I Frederick, Saima Hassan

引用次数: 0

Facing death: the last drawings of a woman with breast cancer at the end of life. 面对死亡：一位患有乳腺癌的女性在生命尽头的最后一幅画。

IF 8.4 2区医学

NPJ Breast Cancer Pub Date : 2026-05-15 DOI: 10.1038/s41523-026-00969-2

Sema Yilmaz Rakici, Bulent Cetin, Esra Aydin, Bilge Gursel

引用次数: 0

Expert recommendations for PIK3CA testing in HR+/HER2- locally advanced and metastatic breast cancer. 专家建议在HR+/HER2-局部晚期和转移性乳腺癌中检测PIK3CA。

IF 8.4 2区医学

NPJ Breast Cancer Pub Date : 2026-05-15 DOI: 10.1038/s41523-026-00968-3

Caterina Marchiò, Federico Rojo, Ellen R Copson, Fernando Schmitt, Beatriz Bellosillo, Carlo Fremd

引用次数: 0

Identification and functional validation of EPS15L1 as a key driver of triple-negative breast cancer. EPS15L1作为三阴性乳腺癌关键驱动因素的鉴定和功能验证

IF 8.4 2区医学

NPJ Breast Cancer Pub Date : 2026-05-15 DOI: 10.1038/s41523-026-00954-9

Chun-Chao Wang, Sabareeswaran Krishnan, Yen-Hsun Wang, Kai-Chen Hsu, Tzu-Sheng Hsu, Chung-Hsing Chen, Shang-Hung Chen, Ren-Hua Chung

{"title":"Identification and functional validation of EPS15L1 as a key driver of triple-negative breast cancer.","authors":"Chun-Chao Wang, Sabareeswaran Krishnan, Yen-Hsun Wang, Kai-Chen Hsu, Tzu-Sheng Hsu, Chung-Hsing Chen, Shang-Hung Chen, Ren-Hua Chung","doi":"10.1038/s41523-026-00954-9","DOIUrl":"10.1038/s41523-026-00954-9","url":null,"abstract":"Triple-negative breast cancer (TNBC) is a heterogeneous and aggressive subtype with no effective targeted therapies. To identify novel therapeutic targets, we conducted transcriptome-wide association studies (TWAS) integrating genome-wide association studies (GWAS) summary statistics from the Breast Cancer Association Consortium (BCAC) and UK Biobank with expression quantitative trait loci (eQTL) summary statistics from breast mammary tissues via the Genotype-Tissue Expression (GTEx) study. Our approach identified novel candidate genes positively or negatively associated with TNBC based on their TWAS effect size. We validated these candidates by confirming their differential expression between TNBC and normal tissues using The Cancer Genome Atlas (TCGA) breast cancer cohort. Among these, Epidermal Growth Factor Receptor Pathway Substrate 15 Like 1 (EPS15L1) emerged as a top candidate significantly associated with TNBC. EPS15L1 was found to be overexpressed in basal-like and claudin-low TNBC tumors and cell lines, with its high expression correlating with poor prognosis. Functional studies demonstrated that EPS15L1 enhances TNBC cell growth, as evidenced by increased metabolic activity in high-density conditions, enhanced clonogenic ability in low-density settings, and improved 3D spheroid formation. Additionally, knockdown of EPS15L1 suppressed the formation and stellate morphology of single-cell-initiated spheroids within the 3D microenvironment. Collectively, these findings establish EPS15L1 as a driver of TNBC initiation, implying its potential as a biomarker for early detection and a target for prevention.","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2026-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13434348/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147948996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

AI-powered and manual assessment of tumor-infiltrating lymphocytes in early HER2-positive breast cancer in NSABP B-41. 人工智能和人工评估早期her2阳性乳腺癌NSABP B-41的肿瘤浸润淋巴细胞。

IF 8.4 2区医学

NPJ Breast Cancer Pub Date : 2026-05-14 DOI: 10.1038/s41523-026-00961-w

Ilana Schlam, Gong Tang, Khalid AbdulJabbar, Haixi Yan, Xuelin Gu, Tanner J Freeman, Sai Maley, Brent T Harris, Priya Rastogi, Isaac Hook, Norman Wolmark, Roberto Salgado, Sandra M Swain

{"title":"AI-powered and manual assessment of tumor-infiltrating lymphocytes in early HER2-positive breast cancer in NSABP B-41.","authors":"Ilana Schlam, Gong Tang, Khalid AbdulJabbar, Haixi Yan, Xuelin Gu, Tanner J Freeman, Sai Maley, Brent T Harris, Priya Rastogi, Isaac Hook, Norman Wolmark, Roberto Salgado, Sandra M Swain","doi":"10.1038/s41523-026-00961-w","DOIUrl":"10.1038/s41523-026-00961-w","url":null,"abstract":"The assessment of tumor-infiltrating lymphocyte (TILs), together with gene expression signatures (GES), has the potential to guide personalized breast cancer therapy. We included 262 patients from the phase III NSABP B-41 trial, which evaluated neoadjuvant HER2-targeted therapies in combination with chemotherapy. We conducted a manual and artificial intelligence (AI)-based analyses of TILs, as well as GES from RNA sequencing. Higher manual TILs as a continuous variable were associated with pathologic complete response (pCR) in patients with estrogen receptor (ER)-negative disease. AI-based TILs were associated with pCR regardless of ER status. Immune GES (iGES) were associated with pCR. Manual TILs were not associated with event-free survival (EFS), while AI-TIL showed a marginal association. These results support the use of TIL assessment, complemented by GES, as a prognostic biomarker in HER2-positive breast cancer. Future studies are needed to evaluate their predictive utility to guide treatment decisions.","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2026-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13415812/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147942141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical significance of residual microcalcifications after neoadjuvant chemotherapy: MRI response and the subtypes. 新辅助化疗后残留微钙化的临床意义：MRI反应及亚型。

IF 8.4 2区医学

NPJ Breast Cancer Pub Date : 2026-05-13 DOI: 10.1038/s41523-026-00960-x

Soong June Bae, Seung Ho Baek, Yoonwon Kook, Joon Jeong, Na Lae Eun, Sung Gwe Ahn

{"title":"Clinical significance of residual microcalcifications after neoadjuvant chemotherapy: MRI response and the subtypes.","authors":"Soong June Bae, Seung Ho Baek, Yoonwon Kook, Joon Jeong, Na Lae Eun, Sung Gwe Ahn","doi":"10.1038/s41523-026-00960-x","DOIUrl":"10.1038/s41523-026-00960-x","url":null,"abstract":"The clinical significance of residual microcalcifications after neoadjuvant chemotherapy (NAC) in breast cancer remains unclear. We aimed to investigate whether residual malignant microcalcifications after NAC are associated with residual malignant disease in patients with breast cancer stratified by subtypes and MRI findings. We collected data retrospectively from January 2007 to December 2022. We evaluated the presence of suspicious microcalcifications on both pre- and post-NAC mammography. We defined a complete MRI response as the resolution of suspicious enhancement in the breast and axilla after NAC. We included 518 patients who had malignant microcalcifications before and after NAC, with 93/518 (18.0%) achieving a complete MRI response. In HR+ HER2-, 158/167 (95.2%) did not achieve pathological complete response (pCR) in breast, regardless of MRI response. Among the complete MRI responders, breast pCR rates were 87.2% (34/39) in HR- HER2+ breast cancer, and 91.7% (11 of 12) in TNBC, and 87.5% (14/16) in HR+ HER2+ breast cancer with limited extent of microcalcifications (<2 cm), respectively. Our findings suggest that despite persistent malignant microcalcifications after NAC, reducing surgical extent might be feasible among highly selected patients by MRI response.","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2026-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13392260/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147931898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Molecular profile of residual triple-negative breast cancer: opportunities for post-neoadjuvant therapeutic interventions. 残余三阴性乳腺癌的分子特征：新辅助治疗干预的机会。

IF 8.4 2区医学

NPJ Breast Cancer Pub Date : 2026-05-13 DOI: 10.1038/s41523-026-00964-7

Nadine S van den Ende, Marcel Smid, John W M Martens, Reno Debets, Agnes Jager, Carolien H M van Deurzen

{"title":"Molecular profile of residual triple-negative breast cancer: opportunities for post-neoadjuvant therapeutic interventions.","authors":"Nadine S van den Ende, Marcel Smid, John W M Martens, Reno Debets, Agnes Jager, Carolien H M van Deurzen","doi":"10.1038/s41523-026-00964-7","DOIUrl":"10.1038/s41523-026-00964-7","url":null,"abstract":"A subset of triple negative breast cancer (TNBC) patients shows resistance to standard neoadjuvant chemotherapy (NAC), resulting in high relapse and mortality risk. This highlights the need for predictive biomarkers and alternative treatment strategies. Targeted molecular profiling was performed on post-NAC resection specimens from 138 TNBC patients, diagnosed across multiple centers between 2013 and 2022, all exhibiting extensive poor response, defined as >50% residual tumor and the development of distant metastasis. Integrated immunohistochemistry and genomic analyses were conducted to identify potentially targetable alterations. Most post-NAC TNBCs (60%) were HER2-ultralow or HER2-low. Among 85 patients with successful DNA sequencing, 2640 variants were detected, with TP53 mutations being most frequent (94%). Mutation count ranged from 3 to 1668 per patient (median n = 11). Several altered genes, including ERBB2, BRCA1/2, PIK3CA, and RB1, have been associated with favorable responses to targeted therapeutics in clinical trials. Moreover, 208 potential neo-peptide targets (median per patient n = 3) were detected across recurrently mutated genes such as ATM, CREBBP, IRS2, KEAP1, MSH6, NOTCH1, NOTCH2, POLD1, TP53, and TSC2. Molecular profiling of residual disease in extensively poor responding TNBC post-NAC revealed multiple potentially targetable variant, supporting the use of next-generation sequencing to guide personalized strategies for these high-risk TNBC patients.","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2026-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13392274/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147931939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Beyond timing, toward precision: insights from CDK4/6 inhibitor trials in metastatic breast cancer. 超越时间，走向精确：CDK4/6抑制剂在转移性乳腺癌中的临床研究

IF 8.4 2区医学

NPJ Breast Cancer Pub Date : 2026-05-12 DOI: 10.1038/s41523-026-00958-5

Serena Di Cosimo, Giovanni Apolone

引用次数: 0

Prediction of OncotypeDX recurrence score using hematoxylin and eosin-stained whole slide images. 苏木精和伊红染色全片图像预测OncotypeDX复发评分。

IF 8.4 2区医学

NPJ Breast Cancer Pub Date : 2026-05-11 DOI: 10.1038/s41523-026-00937-w

Shachar Cohen, Gil Shamai, Edmond Sabo, Alexandra Cretu, Iris Barshack, Tal Goldman, Gil Bar-Sela, Alexander T Pearson, Dezheng Huo, Frederick M Howard, Ron Kimmel, Chen Mayer

{"title":"Prediction of OncotypeDX recurrence score using hematoxylin and eosin-stained whole slide images.","authors":"Shachar Cohen, Gil Shamai, Edmond Sabo, Alexandra Cretu, Iris Barshack, Tal Goldman, Gil Bar-Sela, Alexander T Pearson, Dezheng Huo, Frederick M Howard, Ron Kimmel, Chen Mayer","doi":"10.1038/s41523-026-00937-w","DOIUrl":"10.1038/s41523-026-00937-w","url":null,"abstract":"The OncotypeDX 21-gene assay guides adjuvant chemotherapy decisions in early-stage, hormone receptor-positive, HER2-negative breast cancer, but cost and turnaround time limit access. This study presents a deep learning-based approach for predicting OncotypeDX recurrence scores directly from hematoxylin and eosin-stained whole slide images. Our approach leverages a deep learning foundation model pre-trained on 171,189 slides via self-supervised learning, which is fine-tuned for our task. The model was developed and validated using five independent cohorts, out of which three are external. On the two external cohorts that include OncotypeDX scores, the model achieved an AUC of 0.836 and 0.817, and identified 22% and 16.3% of the patients as low-risk with sensitivity of 0.97 and 0.97 and negative predictive value of 0.97 and 0.96, showing strong generalizability despite variations in staining protocols and imaging devices. Kaplan-Meier analysis demonstrated that patients classified as low-risk by the model had a significantly better prognosis than those classified as high-risk, with a hazard ratio of 4.1 (P < 0.001) and 2.0 (P < 0.01) on the two external cohorts that include patient outcomes. This artificial intelligence-driven solution offers a rapid, cost-effective, and scalable alternative to genomic testing, with the potential to enhance personalized treatment planning, especially in resource-constrained settings.","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2026-05-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13385769/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147874963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Invest where impact begins: recommendations from Breast Cancer Research Foundation Early Career Investigator Working Group (Part 1 of 2). 从影响开始的地方投资：乳腺癌研究基金会早期职业调查员工作组的建议（1 / 2）。

IF 8.4 2区医学

NPJ Breast Cancer Pub Date : 2026-05-11 DOI: 10.1038/s41523-026-00940-1

Yara Abdou, Mariya Rozenblit, Dario Trapani, Ioannis Zerdes, Erin Boudreau, Yang Zhou, Virginie Adam, Carlos Barrios, Chayma Bousrih, Vernal Branch, Lisa A Carey, David Cameron, Samantha Chen, Boon H Chua, Nancy E Davidson, Susan M Domchek, Sarra El-Abed, Dorraya El-Ashry, Margaret Flowers, Julia Foldi, Judy Garber, Theodora Goulioti, Christine Hodgdon, Jessica Lc Hung, Natalie Klar, Larry Norton, Ritesh Parajuli, Martine Piccart, Teri Pollastro, Cesar A Santa-Maria, Eva Schumacher-Wulf, Shane R Stecklein, Anna Thulin, Holly Tovey, Eric Winer, Antonio C Wolff, Nancy U Lin, Seamus O'Reilly

引用次数: 0